SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.  2)*

 

Galera Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

36338D108

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 36338D108 13G Page 2 of 6 Pages

 

1.

Names of Reporting Persons
Novartis Bioventures Ltd.

 
2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

  
  (a) ¨
  (b) ¨
3.

SEC USE ONLY

 
4.

Citizenship or Place of Organization

Switzerland

 

 

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With:

 5.

Sole Voting Power

0

 
6.

Shared Voting Power

476,085

 
7.

Sole Dispositive Power

0

 
8.

Shared Dispositive Power

476,085

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

476,085

 
10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

 ¨
11.

Percent of Class Represented by Amount in Row 9

1.8%

 
12.

Type of Reporting Person (see instructions)

CO

 

 

 

 

 

CUSIP No. 36338D108 13G Page 3 of 6 Pages

 

1.

Names of Reporting Persons
Novartis AG

 
2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

  
  (a) ¨
  (b) ¨
3.

SEC USE ONLY

 
4.

Citizenship or Place of Organization

Switzerland

 

 

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With:

 5.

Sole Voting Power

0

 
6.

Shared Voting Power

476,085

 
7.

Sole Dispositive Power

0

 
8.

Shared Dispositive Power

476,085

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

476,085

 
10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

 ¨
11.

Percent of Class Represented by Amount in Row 9

1.8%

 
12.

Type of Reporting Person (see instructions)

CO

 

 

 

 

 

CUSIP No. 36338D108 13G Page 4 of 6 Pages

 

Item 1(a).

Name of Issuer:

 

Galera Therapeutics, Inc.
   
Item 1(b).

Address of Issuer’s Principal Executive Offices:

 

2 West Liberty Blvd #100, Malvern, PA 19355
   
Item 2(a).

Name of Person Filing:

 

This statement is filed on behalf of the following persons with respect to the shares of Common Stock of the Issuer:

 

(i)          Novartis Bioventures Ltd., a Swiss corporation, with respect to shares held by it; and

 

(ii)         Novartis AG, a Swiss corporation, as the publicly owned parent of Novartis Bioventures Ltd., with respect to the shares held by Novartis Bioventures Ltd

 

The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.”
   
Item 2(b).

Address of Principal Business Office or, if none, Residence:

 

The address of the principal business office of Novartis Bioventures Ltd. and Novartis AG is Lichtstrasse 35, 4056 Basel, Switzerland.
   
Item 2(c).

Citizenship:

 

Novartis Bioventures Ltd. is a corporation organized under the laws of Switzerland and is an indirect wholly-owned subsidiary of Novartis AG.

 

Novartis AG is a corporation organized under the laws of Switzerland and is the publicly owned parent of Novartis Bioventures Ltd.
   
Item 2(d).

Title of Class of Securities:

 

Common Stock, par value $0.001 per share (“Common Stock”).
   
Item 2(e).

CUSIP Number:

 

36338D108.

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)   ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
(b)   ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)   ¨ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
(d)   ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)   ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)   ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)   ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)   ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)   ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)   ¨ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k)   ¨ Group, in accordance with §240.13d–1(b)(1)(ii)(K).
  If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

 

 

 

 

CUSIP No. 36338D108 13G Page 5 of 6 Pages

 

Item 4. Ownership

 

(a) Amount Beneficially Owned:

 

Novartis Bioventures Ltd. is the record owner of 476,085 shares of Common Stock of the Issuer. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to beneficially own these securities.

 

(b) Percent of Class:

 

  1.8%, based on 26,438,767 shares of Common Stock issued and outstanding as of November 5, 2021, as reported by the Issuer in a Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

 

(c) Number of shares as to which the person has:

 

Each Reporting person has:

 

(i) Sole power to vote or to direct the vote: Not applicable

(ii) Shared power to vote or to direct the vote: 476,085

(iii) Sole power to dispose or to direct the disposition of: Not applicable

(iv) Shared power to dispose or to direct the disposition of: 476,085

 

Item 5. Ownership of 5 Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

 

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

 

Not Applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not Applicable

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable

 

 

 

 

CUSIP No. 36338D108 13G Page 6 of 6 Pages

 

Item 9. Notice of Dissolution of a Group

 

Not Applicable

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 11, 2022

  Novartis Bioventures Ltd.
   
  /s/ Bart Dzikowski
  Name: Bart Dzikowski
  Title: Secretary of the Board
   
   
  /s/ Beat Steffen
  Name: Beat Steffen
  Title: Authorized Signatory
   
   
  Novartis AG
   
  /s/ Bart Dzikowski
  Name: Bart Dzikowski
  Title: Authorized Signatory
   
   
  /s/ Beat Steffen
  Name: Beat Steffen
  Title: Authorized Signatory

 

 

 

 

INDEX EXHIBIT

 

SCHEDULE 13G

 

Exhibit Number Exhibit Description
99.3 Joint Filing Agreement

 

 

 

Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more Galera Therapeutics Charts.
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Galera Therapeutics Charts.